

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESOLUTIONS PASSED AT THE 2ND BOARD MEETING FOR FY2026

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 30 March 2026, the Company duly convened its 2nd Board meeting for the financial year ending 31 December 2026 (“FY2026”) via a combination of a physical meeting and teleconference. The meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed:

1. That the Chairman's Report for the financial year ended 31 December 2025 (“FY2025”) be approved;
2. That the Board of Directors' Report for FY2025 be approved;
3. That the full text and summary of the annual report of the Company for FY2025 prepared in accordance with the accounting standards of the People's Republic of China (the “PRC”) and the International Financial Reporting Standards be approved;

To the best of the knowledge of the Directors and management of the Company, there is no other information that would cause the contents of the aforesaid annual report to be false or misleading.

4. That the Company's audited financial report for FY2025 be approved;
5. That the proposed profit distribution plan of the Company for FY2025 be approved;

Based on the audited financial report of the Company for FY2025 prepared by CAC Certified Public Accountants LLP (中审华会计师事务所) in accordance with the PRC accounting standards, the Company recorded a net profit of RMB2,022,668,137.81 for FY2025, and had accumulated undistributed profits of RMB5,500,351,138.82 at the beginning of FY2025. During FY2025, the Company distributed dividends in an aggregate amount of RMB2,872,451,947.88. Accordingly, the accumulated distributable profit of the Company as at the end of FY2025 amounted to RMB4,650,567,328.75.

The Board proposes to declare a final dividend for FY2025 on the basis of RMB23.4 (inclusive of taxes) for every ten (10) shares in the capital of the Company (the “**Proposed Final Dividend**”). Subject to the Proposed Final Dividend being approved by shareholders at the 2026 AGM (as defined below), the Proposed Final Dividend will be paid in respect of all issued shares in the capital of the

Company as at the record date to be determined by the Company for the purposes of determining shareholders' entitlements to the Proposed Final Dividend. The Company will announce the record date and the payment date for the Proposed Final Dividend in due course.

6. That the Company's "Sustainability Report for FY2025" be approved;
7. That the Company's "Self-evaluation Report on Internal Control for FY2025" be approved;
8. That the "Report of the Independent Directors for FY2025" be approved;
9. That the "Report on the Performance of Audit Committee for FY2025" be approved;
10. That the Company's "Special Report on the Deposit and Use of Proceeds for FY2025" be approved;

Please refer to the separate announcement made by the Company on the same day as this announcement in relation to the update on the deposit and use of net proceeds for further details.

11. That the remuneration of S\$55,000 for Independent Director Mr. Yeo Guat Kwang (杨木光) for FY2025 be approved;
12. That the remuneration of S\$55,000 for Independent Director Mr. Liew Yoke Pheng Joseph (刘育彬) for FY2025 be approved;
13. That the remuneration of S\$55,000 for Independent Director Mr. Zhong Ming (钟铭) for FY2025 be approved;
14. That the aggregate remuneration for the Directors of Company for FY2025 be approved;
15. That the aggregate remuneration for senior management (excluding Directors and members of the Supervisory Committee) for FY2025 be approved;
16. That the Company's "Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司)" be approved;

Please refer to the separate announcement made by the Company on the same day as this announcement in relation to the Company's Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) for further details.

17. That the proposed renewal of the shareholders' mandate for interested person transactions be approved;

Further details of the proposed renewal of the shareholders' mandate for interested person transactions will be set out in an annexure to the notice of the 2026 AGM to be issued by the Company in due course.

18. That the proposed Company's "Shareholders' Return Plan for 2026 to 2028" be approved;

Please refer to the separate announcement made by the Company on the same day as this

announcement in relation to the Shareholders' Return Plan for 2026 to 2028 for further details.

19. That the proposed lines of credit granted to the Company up to an aggregate limit of RMB13,455 million be approved;

The Board has approved lines of credit of up to an aggregate limit of RMB13,455 million granted to the Company (including its subsidiaries), and proposes to seek a mandate from the shareholders at a general meeting of the Company to authorise the Company's management, based on the Company's operational needs, to handle the relevant matters relating to loans and other financing arrangements under such lines of credit.

As at the date of this announcement, the Company has received lines of credit from the following banks:

No.	Name of Bank	Line of Credit (RMB million)	Tenor (years)
1.	Agricultural Bank of China Limited, Tianjin Municipal Branch (中国农业银行股份有限公司天津市分行)	1,970	1
2.	Bank of China Limited, Tianjin Municipal Branch (中国银行股份有限公司天津市分行)	750	1
3.	Shanghai Pudong Development Bank Co., Ltd., Tianjin Branch (浦发银行股份有限公司天津分行)	600	1
4.	China CITIC Bank Corporation Limited, Tianjin Branch (中信银行股份有限公司天津分行)	270	1
5.	China Construction Bank Corporation, Tianjin Municipal Branch (中国建设银行股份有限公司天津市分行)	800	1
6.	China Bohai Bank Co., Ltd., Tianjin Branch (渤海银行股份有限公司天津分行)	400	1
7.	Industrial and Commercial Bank of China Limited, Tianjin Branch (中国工商银行股份有限公司天津分行)	300	1
8.	China Merchants Bank Co., Ltd., Tianjin Branch (招商银行股份有限公司天津分行)	500	1
9.	Bank of Communications Co., Ltd., Tianjin Branch (交通银行股份有限公司天津分行)	500	1
10.	Postal Savings Bank of China Co., Ltd., Tianjin Branch (中国邮政储蓄银行天津分行)	450	1
11.	China Minsheng Banking Corp., Ltd., Tianjin Branch (中国民生银行股份有限公司天津分行)	600	1
12.	Industrial Bank Co., Ltd., Tianjin Branch (兴业银行股份有限公司天津分行)	2,000	1
13.	Bank of Shanghai Co., Ltd., Tianjin Branch (上海银行股份有限公司天津分行)	510	1
14.	China Zheshang Bank Co., Ltd., Tianjin Branch (浙商银行股份有限公司天津分行)	400	1
15.	Bank of Beijing Co., Ltd., Tianjin Branch (北京银行股份	5	1

No.	Name of Bank	Line of Credit (RMB million)	Tenor (years)
	有限公司天津分行)		
16.	China Guangfa Bank Co., Ltd., Tianjin Branch (广发银行股份有限公司天津分行)	500	1
17.	Huaxia Bank Co., Ltd., Tianjin Branch (华夏银行股份有限公司天津分行)	200	1
18.	China Everbright Bank Company Limited, Tianjin Branch (光大银行股份有限公司天津分行)	500	1
19.	Ping An Bank Co., Ltd., Tianjin Branch (平安银行股份有限公司天津分行)	300	1
20.	The Export-Import Bank of China, Tianjin Branch (中国进出口银行天津分行)	500	1
21.	Bank of Tianjin Co., Ltd. (天津银行股份有限公司)	200	1
22.	Shengjing Bank Co., Ltd., Tianjin Branch (盛京银行股份有限公司天津分行)	300	1
23.	China Development Bank, Tianjin Municipal Branch (国家开发银行天津市分行)	400	1
24.	Agricultural Development Bank of China, Tianjin Municipal Branch (中国农业发展银行天津市分行)	500	1
Total		13,455	/

20. That the proposed entry into the financial services agreement between the Company and Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) (“**TPGF**”) as an interested person transaction and all transactions arising therefrom be approved;
21. That the proposed provision by the Company, in proportion to its equity interest in Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) (“**Taiping Medicine**”), of a guarantee of up to RMB1,408,875,000 in respect of credit facilities to be obtained by Taiping Medicine from third-party financial institutions as an interested person transaction be approved;
22. That the proposed provision by the Company, in proportion to its indirect equity interest in Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) (“**TJZX Medicine**”) (through Taiping Medicine), of a guarantee of up to RMB1,257,150,000 in respect of credit facilities to be obtained by TJZX Medicine from third-party financial institutions as an interested person transaction be approved;
23. That the proposed provision by the Company, in proportion to its indirect equity interest in TJZX Medicine (through Taiping Medicine), of a guarantee of up to RMB433,500,000 in respect of credit facilities to be obtained by TJZX Medicine from TPGF as an interested person transaction be approved;

Please refer to the separate announcements made by the Company on the same day as this announcement in relation to the interested person transactions referred to in resolutions Nos. 20 to 23 for further details.

24. That the following proposed asset impairment allowance and reversal proposal for the Company for

FY2025 be approved:

- (1) in FY2025, the Company made a bad debts allowance of RMB9,437,500, reversed bad debts allowance of RMB1,118,000, wrote off bad debts against the previously made allowance of RMB11,400, and recorded other reductions of RMB826,800, affecting the current profit and loss of RMB8,319,500;
 - (2) in FY2025, the Company recognised inventory impairment allowance of RMB35,098,100, reversed inventory impairment allowance of RMB108,900, wrote off inventory impairment against the previously recognised allowance of RMB8,926,300, and recorded other reductions of RMB3,751,500, affecting the current profit and loss of RMB34,989,200;
 - (3) in FY2025, the Company made a provision for property, plant and equipment impairment of RMB16,918,700, and wrote off property, plant and equipment impairment against the previously recognised allowance of RMB1,351,300, affecting the current profit and loss of RMB16,918,700;
 - (4) in FY2025, the Company recognised construction in progress impairment allowance of RMB58,303,700, affecting the current profit and loss of RMB58,303,700;
 - (5) in FY2025, the Company recognised intangible assets impairment allowance of RMB29,987,400, affecting the current profit and loss of RMB29,987,400; and
 - (6) in FY2025, the Company recognised a goodwill impairment allowance of RMB12,300,600, affecting the current profit and loss of RMB12,300,600; and
25. That the proposed convening of the annual general meeting for FY2025 (the “**2026 AGM**”) be approved.

The above resolutions Nos. 1, 2, 4, 5, 11 to 14 and 17 to 23 shall be tabled for shareholders' approval at the 2026 AGM to be convened in due course.

Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua, and Ms. Mao Weiwen, being interested Directors in respect of resolutions Nos. 17 and 20 to 23 in relation to interested person transactions, abstained from voting on the relevant resolutions.

The Directors concerned also abstained from voting on the resolutions relating to the approval of their respective remuneration at the Board meeting.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
30 March 2026